Georgiadis et al. considered the issue of antigen escape on the T-cell malignancy populations and established a strategy of CD3 and CD7 CARs combinational therapy to treat T-cell malignancies by genomic editing to remove TCR/CD3 and CD7.42 However, only a small subset of T-ALL expresses CD3, limiting the application of CD3 CAR-T therapy for T-ALL. This evidence concerns the gene CD7 and acute lymphoblastic leukemia.